Search results for "COVID-19 · Heparin · Mortality."

showing 1 items of 1 documents

Prophylactic or therapeutic doses of heparins for COVID-19 infection? A retrospective study

2020

Background: Coronavirus disease 19 (COVID-19) is a global outbreak. COVID-19 patients seem to have relevant coagulative abnormalities, even if they are not typical of disseminated intravascular coagulopathy (DIC) of the kind seen in septicaemia. Therefore, anticoagulant therapy with heparins is increasing in interest for a clinical approach to these patients, particularly if older. Studies comparing if prophylactic doses are more effective than therapeutic ones are still missing. Methods: Data were collected in the Geriatric Section of the Dolo Hospital, ULSS 3 “Serenissima”, Venice from 31st March to 01st May 2020. Heparins (calciparin, fondaparinux, enoxaparine) were divided into prophyla…

Agingmedicine.medical_specialtyCOVID-19 · Heparin · Mortality.Short CommunicationDiseaseFondaparinux03 medical and health sciences0302 clinical medicineInternal medicinemedicineCoagulopathyHumans030212 general & internal medicineMortalitySurvival rateAgedRetrospective StudiesAged 80 and overHeparinSARS-CoV-2business.industryConfoundingHazard ratioAnticoagulantsCOVID-19Retrospective cohort studymedicine.diseaseConfidence intervalFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgerymedicine.drugAging Clinical and Experimental Research
researchProduct